GlassScriptPhysician profile
Philip A Hartman
NPI 1548524457
$4,416.86
in general payments reported to CMS, 2019-2025
34 companies · $205 in 2025
The $205 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,324 · 2020: $789 · 2021: $519 · 2022: $389 · 2023: $722 · 2024: $468 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,395.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $832.80 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $589.99 | 2019-2020 | |
| Novo Nordisk INC | $472.03 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $346.42 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $264.36 | 2019-2025 | |
| Abbott Laboratories | $222.48 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $196.06 | 2019-2023 | |
| Astellas Pharma US INC | $193.07 | 2020-2023 | Myrbetriq, Veozah |
| Allergan, INC. | $170.50 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.09 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $134.96 | 2019-2021 | |
| Glaxosmithkline, LLC. | $133.28 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Supernus Pharmaceuticals, INC. | $124.60 | 2019 | |
| Amarin Pharma, INC. | $61.70 | 2019-2021 | |
| Antares Pharma, INC. | $59.12 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $49.74 | 2020-2021 | |
| Lilly USA, LLC | $48.48 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $44.01 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $37.55 | 2024-2025 | |
| Shire North American Group INC | $29.08 | 2019 | |
| Axsome Therapeutics, INC. | $29.02 | 2023 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.50 | 2019-2024 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $24.08 | 2020-2021 | |
| Genentech USA, INC. | $22.56 | 2019 | |
| Alkermes, INC. | $21.26 | 2025 | Vivitrol |
| Gilead Sciences, INC. | $17.28 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $16.50 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.11 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.75 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.36 | 2019 | |
| Esperion Therapeutics, INC. | $12.25 | 2021 | |
| Eisai INC. | $12.10 | 2019 | |
| Aytu Biopharma, INC. | $11.63 | 2019 | |
| Sanofi Pasteur INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Hartman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.